ABSTRACT
BACKGROUND Statin-induced necrotizing autoimmune myopathy is an exceptionally rare yet severe complication of statin therapy that may develop in individuals at any time during their exposure to statins. The development of proximal muscle weakness, muscle pain, and elevated creatine kinase (CK) levels in patients while taking statins should prompt clinical consideration of statin-induced myopathy. The pathophysiology arises from the production of auto-antibodies, which target the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) enzyme, leading to the aggressive breakdown of myofibrils. CASE REPORT Here, we present a case of a 59-year-old woman with a medical history of dyslipidemia who developed anti-HMG-CoA reductase antibodies after taking atorvastatin. She came to the emergency department with complaints of severe proximal muscle weakness. The laboratory workup showed an elevated CK level up to 12 000 IU/L. Despite discontinuing atorvastatin, the patient's elevated CK levels persisted. The patient underwent a muscle biopsy, demonstrating myofibril necrosis. Serological analysis showed anti-HMG-CoA reductase antibodies in the patient's serum, which led to the diagnosis of immune-mediated necrotizing myopathy due to statins. The patient's statin therapy was promptly discontinued, and she was treated with a high dose of IV corticosteroids. After the patient's discharge, brief discontinuation of the corticosteroids resulted in CK elevation and a return of symptoms. This led to the second re-admission and restarting of corticosteroids until stabilization and discharge. CONCLUSIONS This case represents an important reminder for clinicians to recognize the possibility of statin-induced immune-mediated necrotizing myopathy in patients presenting with proximal muscle weakness while taking a statin, notwithstanding the rarity of this condition.
Subject(s)
Autoimmune Diseases , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Muscular Diseases , Myositis , Female , Humans , Middle Aged , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Atorvastatin/adverse effects , Autoantibodies , Autoimmune Diseases/drug therapy , Myositis/chemically induced , Myositis/diagnosis , Myositis/drug therapy , Muscular Diseases/chemically induced , Muscular Diseases/diagnosis , Muscle Weakness , Adrenal Cortex Hormones/therapeutic useABSTRACT
Cancer screening in idiopathic inflammatory myopathies (IIMs) is essential because an increased risk of cancer in IIMs has been well demonstrated. However, a consensus regarding cancer screening approaches is lacking. Therefore, the approach presented in this review reflects available evidence and our clinical experiences. Patients with IIMs should be evaluated for 3 distinct types of risk categories: (a) clinical with their history, physical examination, and laboratory parameters; (b) based on IIMs subtypes; and (c) based on serology - myositis specific and associated autoantibodies. Further, according to these characteristics, patients should be classified as low risk, moderate risk, and high risk for cancer. In our approach, all patients with IIM within 3 years of disease onset should undertake cancer screening according to their risk stratification. First, irrespective of risk, all patients should undergo age and gender-appropriate screening as per local guidelines. Patients at low-risk stratification should undertake basic cancer screening with routine blood counts, labs, and imaging; at moderate-risk stratification, patients should undertake enhanced cancer screening including CT chest; and at high-risk stratification, patients should undertake comprehensive cancer screening including PET/CT at baseline. Consensus guidelines among all major stakeholders, including rheumatologists, neurologists, dermatologists, and oncologists representing different parts of the world, establishing uniform cancer screening approaches in patients with IIM, are the need of the hour.
Subject(s)
Myositis , Neoplasms , Autoantibodies , Humans , Myositis/diagnosis , Neoplasms/diagnosis , Neoplasms/epidemiology , Positron Emission Tomography Computed TomographyABSTRACT
Giant cell myositis (GCM) is a rare inflammatory myopathy associated with myasthenia gravis and thymoma. Here, we report on a woman in her late 50s with a history of myasthenia gravis, systemic lupus erythematosus and stage IV thymoma with pleural metastases, who presented with proximal weakness, neuromuscular respiratory failure and hypercalcaemia. She was diagnosed with GCM via muscle biopsy and screened for myocarditis but showed no evidence of myocardial involvement. Her hypercalcaemia was consistent with a granulomatous process, likely driven by her GCM. Her strength gradually improved, and her hypercalcaemia did not recur after treatment with high dose steroids, intravenous immune globulin and plasma exchange. Her course was complicated by several opportunistic infections in the setting of her immunosuppression. Despite the high morbidity associated with GCM, she demonstrated clinical improvement after initiating immunosuppressive therapy and continues to be managed in the outpatient setting.
Subject(s)
Hypercalcemia , Myasthenia Gravis , Myositis , Thymoma , Thymus Neoplasms , Female , Giant Cells/pathology , Humans , Hypercalcemia/complications , Myasthenia Gravis/complications , Myositis/diagnosis , Neoplasm Recurrence, Local/pathology , Thymoma/complications , Thymoma/pathology , Thymus Neoplasms/complications , Thymus Neoplasms/pathologyABSTRACT
Hydroxyl-methyl-glutaryl-Co-A reductase (HMGCR) immune mediated necrotising myopathy (IMNM) is a rare autoimmune myositis that is thought to be triggered by statins and responds to immunomodulation. We report a case of a woman in her 30s with HMGCR IMNM without a history of statin exposure who had a clear flare of her myositis after beginning mushroom supplements. Mushrooms are natural HMGCR inhibitors, and this is the first case to demonstrate a flare triggered by mushrooms in a patient with known HMGCR IMNM. This case highlights the importance of reviewing diet and supplements in patients with IMNM. It also emphasises the importance of strict statin avoidance for patients with IMNM even when the myositis is under good control.
Subject(s)
Agaricales , Autoimmune Diseases , Dietary Supplements , Muscular Diseases , Adult , Autoantibodies/immunology , Autoimmune Diseases/chemically induced , Autoimmune Diseases/diagnosis , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Dietary Supplements/adverse effects , Female , Humans , Hydroxymethylglutaryl CoA Reductases/adverse effects , Hydroxymethylglutaryl CoA Reductases/immunology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Muscle, Skeletal/immunology , Muscle, Skeletal/pathology , Muscular Diseases/chemically induced , Muscular Diseases/diagnosis , Muscular Diseases/immunology , Muscular Diseases/pathology , Myositis/chemically induced , Myositis/diagnosis , Myositis/immunology , Myositis/pathology , Necrosis/chemically induced , Necrosis/immunology , Phytotherapy/adverse effects , Symptom Flare UpABSTRACT
OBJECTIVES: Juvenile idiopathic inflammatory myopathies (JIIMs) are a heterogeneous group of systemic autoimmune diseases. Juvenile dermatomyositis (JDM) is the predominant form of JIIMs, and is a rare, chronic autoimmune illness characterised by symmetric, proximal muscle damages and involvement of the skin. In the last two decades, the use of monoclonal antibodies has also been expanded to JIIMs; however, there is limited evidence on use of these treatments. We assessed the efficacy/effectiveness and safety of biologic agents in JIIMs. METHODS: A systematic literature review was conducted using Embase®, MEDLINE®, MEDLINE®-In Process and Cochrane library to identify studies on biologics agents in JIIMs published in English language as full-text articles (1975 to December 2020) or conference abstracts (2000 to December 2020). Databases were searched with the key words regarding chronic myositis crossed with "biologic agents OR tocilizumab OR rituximab OR adalimumab OR infliximab OR anti-TNF OR etanercept". Of note, we did not include children, age, or age limits in the search as medical subject headings terms because we may have been able to extract a sub cohort of children from studies including both children and adults. RESULTS: Of the 1633 retrieved publications, 18 articles were identified for a total of 165 patients. In real-world studies, definition of complete (CR) or partial response (PR) varied. JIIMs patients were most often treated with anti-TNF (88 pts); patients received etanercept (ETA), 48 patients infliximab (IFX), 4 patients received adalimumab (ADA). In other 15 patients IFX was followed by ADA. Rituximab (RTX) was used in 73 children. A single case series reported the use of abatacept (ABA) in 4 patients. Despite the reduced number of treated patients, complete response on myositis was reported in 29.6% (8/26) patients treated with at least one anti-TNF and in 38% (10/26) treated by RTX. Complete response of skin vasculitis has been reached in 33% (4/12) children on anti-TNF and in 36% on RTX (21/58). Anti-TNF agents might be efficient in treating calcinosis lesions. CONCLUSIONS: Currently, the available evidence regarding the use of biologic treatment in JIIMs results quite limited but suggest a promising the use of anti-TNF agents and RTX in treating active JIIMs. Anti-TNF treatment might have a role in treating calcinosis. However, an overall very low quality of the available studies and multiple confounding factors hamper to suggest a treatment over another. Thus, randomised clinical trials are urgently required to attempt the optimal treatment in real-world setting.
Subject(s)
Antirheumatic Agents , Biological Products , Myositis , Adalimumab/therapeutic use , Adult , Antirheumatic Agents/therapeutic use , Biological Products/adverse effects , Biological Therapy , Child , Etanercept/therapeutic use , Humans , Infliximab/therapeutic use , Myositis/diagnosis , Myositis/drug therapy , Precision Medicine , Tumor Necrosis Factor Inhibitors/therapeutic useABSTRACT
BACKGROUND: Resection of colorectal cancer (CRC) initiates inflammation, mediated at least partly by NFĸB (nuclear factor kappa-light-chain-enhancer of activated B-cells), leading to muscle catabolism and reduced physical performance. Eicosapentaenoic acid (EPA) has been shown to modulate NFĸB, but evidence for its benefit around the time of surgery is limited. OBJECTIVE: To assess the effect of EPA supplementation on muscle inflammation and physical function around the time of major surgery. DESIGN: In a double-blind randomized control trial, 61 patients (age: 68.3 ± 0.95 y; 42 male) scheduled for CRC resection, received 3 g per day of EPA (n = 32) or placebo (n = 29) for 5-days before and 21-days after operation. Lean muscle mass (LMM) (via dual energy X-ray absorptiometry (DXA)), anaerobic threshold (AT) (via cardiopulmonary exercise testing (CPET)) and hand-grip strength (HG) were assessed before and 4-weeks after surgery, with muscle biopsies (m. vastus lateralis) obtained for the assessment of NF-ĸB protein expression. RESULTS: There were no differences in muscle NFĸB between EPA and placebo groups (mean difference (MD) -0.002; 95% confidence interval (CI) -0.19 to 0.19); p = 0.98). There was no difference in LMM (MD 704.77 g; 95% CI -1045.6 g-2455.13 g; p = 0.42) or AT (MD 1.11 mls/kg/min; 95% CI -0.52 mls/kg/min to 2.74 mls/kg/min; p = 0.18) between the groups. Similarly, there was no difference between the groups in HG at follow up (MD 0.1; 95% CI -1.88 to 2.08; p = 0.81). Results were similar when missing data was imputed. CONCLUSION: EPA supplementation confers no benefit in terms of inflammatory status, as judged by NFĸB, or preservation of LMM, aerobic capacity or physical function following major colorectal surgery. CLINICAL TRIALS REFERENCE: NCT01320319.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Colectomy , Colorectal Neoplasms/surgery , Dietary Supplements , Eicosapentaenoic Acid/therapeutic use , Muscle, Skeletal/drug effects , Myositis/drug therapy , Aged , Anti-Inflammatory Agents/adverse effects , Body Composition , Colectomy/adverse effects , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/physiopathology , Dietary Supplements/adverse effects , Double-Blind Method , Eicosapentaenoic Acid/adverse effects , England , Female , Functional Status , Hand Strength , Humans , Inflammation Mediators/metabolism , Male , Middle Aged , Muscle, Skeletal/metabolism , Muscle, Skeletal/physiopathology , Myositis/diagnosis , Myositis/metabolism , Myositis/physiopathology , NF-kappa B/metabolism , Treatment OutcomeABSTRACT
A 61-year-old Hispanic man presented to a county hospital for subacute progressive weakness, heliotrope rash and dysphagia. There was initial suspicion for dermatomyositis (DM) given the history; however, the physical exam was not consistent. An MRI followed by a muscle biopsy revealed necrotising autoimmune myositis and anti-3-hydroxy-3-methylglutary-coenzyme A-reductase antibody titers returned positive; the patient was diagnosed with necrotising autoimmune myositis. He was treated with corticosteroids and intravenous immunoglobulin, which resulted in improvement in his weakness and functional status. This case represents a unique instance in which a cardinal feature of DM, the heliotrope rash, prompted an erroneous initial diagnosis. It highlights the necessity of developing abroad differential diagnosis and subsequent thorough investigation into patients presenting with suspected idiopathic immune-mediated myopathies.
Subject(s)
Adrenal Cortex Hormones/therapeutic use , Hispanic or Latino , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Muscle, Skeletal/pathology , Myositis/diagnosis , Necrosis/pathology , Autoantibodies/blood , Humans , Male , Middle Aged , Myositis/drug therapy , Myositis/physiopathology , Necrosis/drug therapy , Treatment OutcomeABSTRACT
We describe the successful management of Anncaliia algerae microsporidial myositis in a man with graft versus host disease after hemopoietic stem cell transplantation. We also summarize clinical presentation and management approaches and discuss the importance of research into the acquisition of this infection and strategies for prevention.
Subject(s)
Albendazole/therapeutic use , Antiprotozoal Agents/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Microsporidia/isolation & purification , Myositis/drug therapy , Spores, Fungal/isolation & purification , Aged , Graft vs Host Disease/drug therapy , Graft vs Host Disease/etiology , Graft vs Host Disease/immunology , Graft vs Host Disease/pathology , Humans , Immunosuppressive Agents/therapeutic use , Male , Microsporidia/drug effects , Microsporidia/pathogenicity , Myositis/diagnosis , Myositis/immunology , Myositis/microbiology , New South Wales , Spores, Fungal/drug effects , Spores, Fungal/pathogenicity , Transplantation, HomologousABSTRACT
Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) was described in 2011. Over time the condition and its triggers have broadened to include several autoimmune disorders, the macrophagic myofasciitis syndrome, the Gulf war syndrome, the sick building syndrome, siliconosis, and the chronic fatigue syndrome. The aluminum-containing adjuvants in the hepatitis B vaccine and the human papillomavirus vaccine in particular have been stated to be the major causes of the disorder. Here, we review the specificity of the diagnostic criteria for ASIA. We also examine relevant human data, pertaining to causation, particularly from patients undergoing allergen-specific immunotherapy (IT). Patients undergoing allergen-specific IT receive 100 to 500 times more injected aluminum over 3 to 5 years, compared with hepatitis B and human papillomavirus vaccine recipients. In a large pharmacoepidemiological study, in contrast to case series of ASIA, patients receiving aluminum-containing allergen IT preparations were shown to have a lower incidence of autoimmune disease. In another clinical trial, there were no increases in exacerbations in a cohort of patients with systemic lupus erythematosus immunized with the hepatitis B vaccine. Current data do not support the causation of ASIA by vaccine adjuvants containing aluminum, which should be of reassurance to patients undergoing routine immunizations as well as to those undergoing allergen-specific IT.
Subject(s)
Adjuvants, Immunologic/adverse effects , Aluminum/adverse effects , Autoimmune Diseases/diagnosis , Desensitization, Immunologic/methods , Fasciitis/diagnosis , Fatigue Syndrome, Chronic/diagnosis , Myositis/diagnosis , Persian Gulf Syndrome/diagnosis , Allergens/immunology , Aluminum/immunology , Autoimmune Diseases/etiology , Clinical Trials as Topic , Desensitization, Immunologic/adverse effects , Diagnosis, Differential , Fasciitis/etiology , Fatigue Syndrome, Chronic/etiology , Hepatitis B Vaccines/adverse effects , Hepatitis B Vaccines/immunology , Humans , Inflammation , Mass Vaccination , Myositis/etiology , Papillomavirus Vaccines/adverse effects , Papillomavirus Vaccines/immunology , Persian Gulf Syndrome/etiologyABSTRACT
Recently Shoenfeld and Agmon-Levin proposed a new clinical entity called autoimmune/inflammatory syndrome induced by adjuvants (ASIA), which includes four clinical entities called: 1) siliconosis, 2) Gulf War syndrome, 3) macrophage myofasciitis) and 4) post-vaccination phenomenon associated with adjuvants. They all have a common denominator: a prior exposure to immunoadjuvants, and, in addition, they also share several clinical criteria associated to chronic inflammation and autoimmune reactions. This proposal still needs to be validated by the scientific community, but nowadays is a topic of hot discussion in the literature and in various international conferences. In this revision article, we analyze the characteristics of this syndrome, the current mechanisms possibly involved in the pathogenesis, and the more recent reports regarding ASIA associated to vaccine and some foreign substances.
Recientemente Shoenfeld y Agmon-Levin han propuesto una nueva entidad clínica denominada síndrome autoinmune/inflamatorio inducido por adyuvantes (ASIA, por sus siglas en inglés), el cual incluye cuatro entidades denominadas: 1) siliconosis, 2) síndrome de la guerra del Golfo, 3) miofascitis macrofágica y 4) fenómeno posvacunación asociado a adyuvantes. Todos ellos tienen un denominador común: una exposición previa a inmunoadyuvantes y además comparten varios criterios clínicos asociados a inflamación crónica y reacciones autoinmunes. Esta propuesta aún debe ser validada por la comunidad científica, pero hoy en día es un tema de intenso debate en la literatura biomédica y en varias conferencias internacionales. En esta revisión, se analizan las características de este síndrome, los mecanismos actuales posiblemente implicados en la patogénesis y los más recientes informes sobre ASIA asociada a vacunas y a algunas sustancias extrañas.
Subject(s)
Adjuvants, Immunologic/adverse effects , Autoimmune Diseases/diagnosis , Fasciitis/diagnosis , Inflammation/diagnosis , Myositis/diagnosis , Persian Gulf Syndrome/diagnosis , Silicones/adverse effects , Vaccines/adverse effects , Autoimmune Diseases/etiology , Environmental Exposure/adverse effects , Fasciitis/etiology , Humans , Inflammation/etiology , Myositis/etiology , Persian Gulf Syndrome/etiology , SyndromeABSTRACT
BACKGROUND: Approximately 10-50% of chest pains are caused by musculoskeletal disorders. The association is twice as frequent in primary care as in emergency admissions. AIM: This article provides an overview of the most important musculoskeletal causes of chest pain and on the diagnostics and therapy. METHODS: A selective search and analysis of the literature related to the topic of musculoskeletal causes of chest pain were carried out. RESULTS AND CONCLUSION: Non-inflammatory diseases, such as costochondritis and fibromyalgia are frequent causes of chest pain. Inflammatory diseases, such as rheumatoid arthritis, spondyloarthritis and systemic lupus erythematosus are much less common but are more severe conditions and therefore have to be diagnosed and treated. The diagnostics and treatment often necessitate interdisciplinary approaches. Chest pain caused by musculoskeletal diseases always represents a diagnosis by exclusion of other severe diseases of the heart, lungs and stomach. Physiotherapeutic and physical treatment measures are particularly important, including manual therapy, transcutaneous electrical stimulation and stabilization exercises, especially for functional myofascial disorders.
Subject(s)
Chest Pain/diagnosis , Chest Pain/prevention & control , Joint Diseases/diagnosis , Joint Diseases/therapy , Myositis/diagnosis , Myositis/therapy , Anti-Inflammatory Agents/administration & dosage , Chest Pain/etiology , Combined Modality Therapy/methods , Diagnosis, Differential , Evidence-Based Medicine , Humans , Joint Diseases/complications , Myositis/complications , Physical Therapy Modalities , Transcutaneous Electric Nerve Stimulation/methods , Treatment OutcomeABSTRACT
La miotonía congénita es la forma más común de miotonía no distrófica. Esta miopatía está causada por mutaciones en el gen CLCN1, codificante del principal canal de iones cloruro del músculo esquelético (ClC-1); la alteración de la función de este canal, regulado por voltaje, da lugar al fenómeno de miotonía. La enfermedad se puede heredar con un tipo de herencia dominante (enfermedad de Thomsen) o recesiva (enfermedad de Becker o miotonía congénita generalizada). El fenotipo clínico de ambas formas de la enfermedad es similar aunque la forma recesiva se caracteriza por una mayor gravedad de los síntomas. El diagnóstico clínico de miotonía congénita debe sospecharse cuando encontramos en un paciente episodios de rigidez muscular (miotonía), remisión o alivio de la rigidez con el ejercicio (fenómeno warm-up), miotonía clínica, un patrón electromiográfico característico y/o historia familiar. El diagnóstico molecular de miotonía congénita consiste en el análisis por secuenciación del gen CLCN1 (AU)
Myotonia congenita is the most common form of non-dystrophic myotonia. This myopathy is caused by mutations in the CLCN1 gene, encoding the main skeletal muscle chloride ion channel (ClC-1). Altering the function of this voltage-gated channel, leads to the phenomenon of myotonia. The disease can be inherited with a dominant (Thomsen disease) or recessive type (Becker disease or congenital generalised myotonia). The clinical phenotype of both forms of the disease is similar, although the recessive form is characterised by more severe symptoms. The clinical diagnosis of congenital myotonia should be suspected in a patient who presents with episodes of muscle stiffness (myotonia), remission or relief from stiffness with exercise (warm-up phenomenon), and a characteristic electromyography pattern, and/or family history. Sequencing the CLCN1 gene is the present approach for molecular diagnosis of myotonia congenita (AU)
Subject(s)
Humans , Male , Female , Myotonia Congenita/diagnosis , Myotonia Congenita/genetics , Myositis/complications , Myositis/diagnosis , Mutagenesis/genetics , Molecular Biology/methods , Diagnosis, Differential , Clinical Diagnosis/diagnosis , Clinical Diagnosis/trends , Myotonic Disorders/diagnosis , Myotonic Disorders/genetics , Muscular Dystrophy, Duchenne/complications , Muscular Dystrophy, Duchenne/diagnosisSubject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Arthritis/drug therapy , Biological Therapy/methods , Ligases/antagonists & inhibitors , Lung Diseases, Interstitial/drug therapy , Myositis/drug therapy , Adult , Arthritis/complications , Arthritis/diagnosis , Female , Humans , Lung Diseases, Interstitial/complications , Lung Diseases, Interstitial/diagnosis , Magnetic Resonance Imaging , Myositis/complications , Myositis/diagnosis , Radiography , SyndromeABSTRACT
Up to 50% patients with sarcoidosis display extra-pulmonary disease. However, initial and isolated (ie, without lung disease) acute muscular involvement associated with pseudo-malignant hypercalcemia is very uncommon. We report on 3 cases of life-threatening hypercalcemia revealing florid and isolated acute sarcoid-like myositis.All patients complained of fatigue, progressive general muscle weakness, and weight loss. Laboratory tests showed a severe life-threatening hypercalcemia (>3.4âmmol/L). Hypercalcemia was associated with increased serum level of 1,25-(OH)2 vitamin D and complicated with acute renal failure. One patient displayed acute pancreatitis due to hypercalcemia.In all cases, PET-scan, performed for malignancy screening, incidentally revealed an intense, diffuse, and isolated muscular fluorodeoxyglucose (FDG) uptake consistent with diffuse non-necrotizing giant cells granulomatous myositis demonstrated by muscle biopsy. Of note, creatine phosphokinase blood level was normal in all cases. No patients displayed the usual thoracic features of sarcoidosis.All patients were treated with high dose steroids and achieved rapid, complete, and sustained remission. A review of English and French publications in Medline revealed 5 similar published cases.Steroid-sensitive acute sarcoid-like myositis causing high calcitriol levels and life-threatening hypercalcemia should be recognized as a separate entity.
Subject(s)
Hypercalcemia/etiology , Myositis/complications , Paraneoplastic Syndromes/etiology , Sarcoidosis/complications , Acute Disease , Adult , Aged , Biopsy , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Hypercalcemia/diagnosis , Male , Middle Aged , Myositis/diagnosis , Paraneoplastic Syndromes/diagnosis , Positron-Emission Tomography , Sarcoidosis/diagnosisSubject(s)
Myositis/complications , Ocular Motility Disorders/etiology , Oculomotor Muscles , Child , Dose-Response Relationship, Drug , Eye Movement Desensitization Reprocessing , Female , Glucocorticoids/administration & dosage , Humans , Myositis/diagnosis , Myositis/drug therapy , Ocular Motility Disorders/diagnosis , Ocular Motility Disorders/drug therapy , Prednisolone/administration & dosage , Syndrome , Tomography, X-Ray ComputedABSTRACT
OBJECTIVES: To assess the efficacy and safety of B-lymphocyte depletion therapy (BCDT) utilising rituximab in refractory idiopathic inflammatory myositis. METHODS: We retrospectively evaluated 16 adult patients with active dermatomyositis (DM) or polymyositis (PM) who received 1 gram rituximab intravenous infusions two weeks apart after failing to respond to conventional therapy. The clinical and biochemical response were analysed by the Myositis Intention to Treat index (MITAX) and the serum creatine kinase (CK) levels at baseline and 6 and 12 months after treatment. The primary efficacy outcome was 20% improvement in the MITAX index and 30% reduction in CK. RESULTS: Eight patients responded to treatment and achieved both the MITAX and CK levels objectives within 6 months of rituximab therapy. Five out of these 8 responders remained clinically stable at 12 months and CK levels were still reduced or normalised. Of note, 4 patients who did not respond were re-assessed and had their diagnoses corrected. All patients showed adequate B cell depletion (BCD) with re-population occurring for a 15.4 months average (range 3-42 months). Those simultaneously treated with cyclophosphamide achieved more long-lasting depletion (average 18.6 months). CONCLUSIONS: The heterogeneous clinical and serological characteristics of patients diagnosed with IIM probably explain why some, but not all patients respond to rituximab. Myositis overlap and anti-synthetase syndromes seem to respond better than other patient subsets.
Subject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Immunologic Factors/therapeutic use , Myositis/drug therapy , Adult , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antibodies, Monoclonal, Murine-Derived/adverse effects , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Biomarkers/blood , Creatine Kinase/blood , Drug Administration Schedule , Female , Humans , Immunologic Factors/administration & dosage , Immunologic Factors/adverse effects , Infusions, Intravenous , Male , Middle Aged , Myositis/blood , Myositis/diagnosis , Myositis/immunology , Remission Induction , Retrospective Studies , Rituximab , Time Factors , Treatment OutcomeABSTRACT
All-trans retinoic acid has revolutionized the treatment of acute promyelocytic leukemia, but this therapy is often complicated by the all-trans retinoic acid syndrome. Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy. We review the existing literature on this rare clinical entity, all-trans retinoic acid-induced myositis. This condition can manifest as fever, myalgia, arthralgia, and Sweet syndrome, accompanied by distinct magnetic resonance findings involving the lower extremity musculature. Treatment consists of discontinuation of the offending drug and often high dose corticosteroids.
Subject(s)
Mononeuropathies/chemically induced , Myositis/chemically induced , Synovitis/chemically induced , Tretinoin/adverse effects , Adrenal Cortex Hormones/therapeutic use , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Female , Humans , Leukemia, Promyelocytic, Acute/drug therapy , Middle Aged , Mononeuropathies/diagnosis , Mononeuropathies/drug therapy , Myositis/diagnosis , Myositis/drug therapy , Synovitis/diagnosis , Synovitis/drug therapy , Treatment Outcome , Tretinoin/therapeutic use , Withholding TreatmentABSTRACT
CONTEXT: Chronic, nonspecific back pain is a ubiquitous problem that has frustrated both physicians and patients. Some have suggested that it is time for a "paradigm shift" in treating it. One of them is John Sarno, MD, of New York University's Rusk Institute of Rehabilitation, who has argued for this in 4 books and several journal publications. We believe that a mind-body approach is more effective and involves much less risk and expense than conventional approaches in appropriately diagnosed cases. OBJECTIVE: To determine if a mind-body treatment program addressing a presumed psychological etiology of persistent back pain merits further research. DESIGN: Case series outcome study. SETTING: Single physician's office in metropolitan Los Angeles. PATIENTS: Fifty-one patients with chronic back pain, diagnosed with tension myositis syndrome, a diagnosis for "functional" back pain and treated in the principal investigator's office in 2002 and 2003. INTERVENTIONS: A program of office visits, written educational materials, a structured workbook (guided journal), educational audio CDs, and, in some cases, individual psychotherapy. MAIN OUTCOME MEASURES: Pain intensity (visual analog scale scores), quality of life (RAND SF-12), medication usage, and activity level (questionnaires). Follow-up was at least 3 to 12 months after treatment. RESULTS: Mean VAS scores decreased 52% for "average" pain (P < .0001), 35% for "worst" pain (P < .0001), and 65% for "least" pain (P < .0001). SF-12 Physical Health scores rose >9 units (P = .005). Medication usage decreased (P = .0008). Activity levels increased (P =.03). Participants aged >47 years and in pain for >3 years benefited most.
Subject(s)
Back Pain/therapy , Mental Health , Mind-Body Relations, Metaphysical , Myositis/therapy , Spirituality , Adult , Aged , Back Pain/diagnosis , Back Pain/etiology , Back Pain/psychology , California , Chronic Disease , Female , Humans , Logistic Models , Male , Middle Aged , Myositis/complications , Myositis/diagnosis , Myositis/psychology , Research Design , Self Care , Syndrome , Treatment OutcomeABSTRACT
Transcutaneous electrical nerve stimulation (TENS) reduces pain through central mechanisms involving spinal cord and brainstem sites. Since TENS acts through central mechanisms, we hypothesized that TENS will reduce chronic bilateral hyperalgesia produced by unilateral inflammation when applied either ipsilateral or contralateral to the site of muscle inflammation. Sprague-Dawley rats were injected with carrageenan in the left gastrocnemius muscle belly. Mechanical withdrawal threshold was tested bilaterally before and 2 weeks after carrageenan injection. After testing withdrawal thresholds at 2 weeks, rats received TENS treatment either ipsilateral or contralateral to the site of inflammation. In each of these groups, rats were randomized to control (no TENS), low frequency (4 Hz), or high frequency (100 Hz) TENS treatment. TENS was applied for 20 min at sensory intensity under light halothane anesthesia. Mechanical withdrawal thresholds were re-assessed after TENS or 'no TENS' treatment. Unilateral injection of carrageenan to the gastrocnemius muscle significantly reduced the mechanical withdrawal threshold (mechanical hyperalgesia) bilaterally 2 weeks later. Either low or high frequency TENS applied to the gastrocnemius muscle ipsilateral to the site of inflammation significantly reversed mechanical hyperalgesia, both ipsilateral and contralateral to the site of inflammation. Low or high frequency TENS applied to the gastrocnemius muscle contralateral to the site of inflammation also significantly reduced mechanical hyperalgesia, both ipsilateral and contralateral to the site of inflammation. Since ipsilateral or contralateral TENS treatments were effective in reducing chronic bilateral hyperalgesia in this animal model, we suggest that TENS act through modulating descending influences from supraspinal sites such as rostral ventromedial medulla (RVM).